Gilead Raday - 01 Oct 2026 Form 4 Insider Report for RedHill Biopharma Ltd. (RDHL)

Reporting relationship: Chief Operating Officer
Issuer ticker: RDHL
Reported as of: 01 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Oct 2026, 07:00:16 UTC
Prior SEC filing: 13 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Gilead Raday

Filing notes and source

Key filing fact

Gilead Raday filed Form 4 for RedHill Biopharma Ltd. (RDHL) on 06 Oct 2026.

Key facts

This page summarizes Gilead Raday's Form 4 filing for RedHill Biopharma Ltd. (RDHL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Oct 2026, 07:00.

Change

Previous filing in this sequence was filed on 13 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002113137 Primary reporting owner

Raday Gilead

Relationship: Chief Operating Officer
Address: 21 HA'ARBA'A STREET, TEL AVIV, ISRAEL
Signature: /s/ Gilead Raday
Signature date: 06 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RDHL transaction

Ordinary Shares

Sale

Transaction value
Shares: -14,310,000
Change %: -7.5%
Price: $0.000100^*
Shares after: 176,910,000
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RDHL transaction Derivative

American Depository Shares

Options Exercise

Transaction value
Shares: +27,560,000
Change %: +26%
Price: $0.000000^*
Shares after: 131,690,000
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 27,560,000
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reporting person sold 1,431 American Depository Shares ("ADS"), of RedHill Biopharma Ltd. (the "Issuer"), each ADS represents 10,000 ordinary shares, which have no par value effective August 7, 2026, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,187 Restricted Share Units ("RSU") granted to him on March 26, 2025, and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person.

Footnote F2

The price reported in Table 1 Column 4 is $0.465 per ADS, which would be equivalent to $0.0000465 per ordinary share.

Footnote F3

Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.